Abstract
Methods for selective chemical modification of the antibiotic olivomycin A (OA) were developed at G. F. Gause Institute of New Antibiotics. The compound with the highest activity against various tumor cell lines was selected from a series of OA analogs. The aim of the work was to study the antitumor activity and toxicity of a dosage form of this compound, i.e., olivamide. Antitumor activity was studied in four syngenic grafted murine tumors. Chronic toxicity was assessed in experiments with rats that determined the animal body mass, clinical and biochemical blood analysis, urinalysis, electrocardiography, and structures of internal organs. The preparation exhibited high antitumor activity and displayed dose-dependent nephro- and hepatotoxic properties.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
